论文部分内容阅读
目的 检测肿瘤特异性共享抗原NY ESO 1/LAGE 1基因在肝癌中的表达情况及其诱导肝癌患者体液免疫应答的能力 ,为利用NY ESO 1/LAGE 1为抗原进行肝癌的疫苗免疫治疗提供依据。方法 利用逆转录 聚合酶链反应 (RT PCR)方法检测了 34例肝癌患者癌和癌旁组织NY ESO 1/LAGE 1基因mRNA水平的表达 ;利用酶联免疫吸附实验检测了NY ESO 1/LAGE 1在 37例肝癌患者中诱导自身抗体产生的能力。结果 34例肝癌组织中 9例 ( 2 6 .5 % )表达NY ESO 1,12例 ( 35 3% )表达LAGE 1。其中 ,同一标本中共表达NY ESO 1/LAGE 1的病例数为 7例 ;表达其中至少一种基因的14例 ,占总数的 4 1.2 %。所检测的 37份肝癌患者血清中 ,6例患者血清抗NY ESO 1抗体阳性 ,5例为Ⅲ期及以上患者 ,1例为Ⅱ期患者。结论 NY ESO 1/LAGE 1在肝癌患者中表达率较高 ,并可诱导自身体液免疫应答 ,提示可作为疫苗的备选抗原成分
Objective To detect the expression of NY-ESO 1 / LAGE 1 gene in hepatocellular carcinoma (HCC) and its ability to induce humoral immune response in patients with hepatocellular carcinoma (HCC), so as to provide evidence for the immunotherapy with NY ESO 1 / LAGE 1 as antigen. Methods The mRNA levels of NY ESO 1 / LAGE 1 gene were detected by reverse transcription polymerase chain reaction (RT PCR) in 34 cases of HCC patients. The NY ESO 1 / LAGE 1 gene was detected by enzyme-linked immunosorbent assay (ELISA) The ability to induce autoantibodies in 37 HCC patients. Results Nine of the 34 HCC tissues (26.5%) expressed NY ESO and 12 (35.3%) expressed LAGE 1. Among them, seven cases were co-expressed with NY ESO 1 / LAGE 1 in the same specimen, and 14 cases with at least one gene were expressed, accounting for 4 1.2% of the total. Among the 37 serum samples from liver cancer patients, 6 were positive for anti-NY ESO 1 antibody, 5 were in stage III and above, and 1 were in stage II. Conclusion NY ESO 1 / LAGE 1 is highly expressed in patients with HCC and can induce its own humoral immune response, suggesting that NY ESO 1 / LAGE 1 may be an alternative antigenic component of the vaccine